Debbie M. Roeleveld
Nijmegen, GE, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Systemic overexpression of interleukin-22 induces the negative immune-regulator SOCS3 and potently reduces experimental arthritis in mice.
Journal: Rheumatology (Oxford, England)
Published: February 21, 2020
Microbiota-Dependent Involvement of Th17 Cells in Murine Models of Inflammatory Arthritis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: August 31, 2017
Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritis.
Journal: Rheumatology (Oxford, England)
Published: March 22, 2017
Higher efficacy of anti-IL-6/IL-21 combination therapy compared to monotherapy in the induction phase of Th17-driven experimental arthritis.
Journal: PloS one
Published: October 12, 2016
In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone Marrow.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: May 23, 2016
A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics.
Journal: Blood
Published: November 08, 2014
The Th17 pathway as a therapeutic target in rheumatoid arthritis and other autoimmune and inflammatory disorders.
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: April 27, 2013
GM-CSF as a therapeutic target in inflammatory diseases.
Journal: Molecular immunology
Published: March 14, 2013
Interleukin-21 receptor deficiency increases the initial toll-like receptor 2 response but protects against joint pathology by reducing Th1 and Th17 cells during streptococcal cell wall arthritis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: January 20, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026